---
title: "CCC Intelligent Solutions | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 587.3 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294188064.md"
datetime: "2026-07-29T10:09:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294188064.md)
  - [en](https://longbridge.com/en/news/294188064.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294188064.md)
---

# CCC Intelligent Solutions | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 587.3 M

Revenue: As of FY2026 Q2, the actual value is USD 587.3 M, beating the estimate of USD 284.08 M.

EPS: As of FY2026 Q2, the actual value is USD -0.42.

EBIT: As of FY2026 Q2, the actual value is USD -200.2 M.

### Q2 & H1 2026 Financial Results

#### Revenue

-   Q2 2026 Revenue was $587 million, a change of -$34 million from Q2 2025.
-   H1 2026 Revenue was $1,173 million, a change of -$42 million from H1 2025.
-   The change in revenue was primarily due to inorganic disposals.

#### Operating Expenses

-   Q2 2026 Operating Expenses were $787 million, an increase of $173 million from Q2 2025.
-   H1 2026 Operating Expenses were $1,343 million, an increase of $114 million from H1 2025.

#### Income / (Loss) from Operations

-   Q2 2026 Income / (Loss) from Operations was -$200 million, a change of -$207 million from Q2 2025.
-   H1 2026 Income / (Loss) from Operations was -$170 million, a change of -$156 million from H1 2025.

#### Net Income / (Loss)

-   Q2 2026 Net Income / (Loss) was -$269 million, a change of -$197 million from Q2 2025.
-   H1 2026 Net Income / (Loss) was -$309 million, a change of -$133 million from H1 2025.
-   The loss and change over the prior year were entirely due to a non-cash goodwill impairment charge associated with the Life Sciences & Healthcare (LS&H) divestiture.

#### Adjusted EBITDA

-   Q2 2026 Adjusted EBITDA was $247 million, a change of -$14 million from Q2 2025.
-   H1 2026 Adjusted EBITDA was $488 million, a change of -$6 million from H1 2025.

#### Adjusted EBITDA Margin

-   Q2 2026 Adjusted EBITDA Margin was 42.1%, which was flat compared to Q2 2025.
-   H1 2026 Adjusted EBITDA Margin was 41.6%, an increase of 90 bps from H1 2025.

#### Operating Cash Flow

-   Q2 2026 Operating Cash Flow was $99 million, a change of -$17 million from Q2 2025.
-   H1 2026 Operating Cash Flow was $233 million, a change of -$54 million from H1 2025.
-   The change was primarily due to lower Adjusted EBITDA, with lower interest offset by higher working capital requirements.

#### Capital Spending

-   Q2 2026 Capital Spending was -$55 million, a change of $11 million from Q2 2025.
-   H1 2026 Capital Spending was -$111 million, a change of $16 million from H1 2025.

#### Free Cash Flow

-   Q2 2026 Free Cash Flow was $44 million, a change of -$6 million from Q2 2025.
-   H1 2026 Free Cash Flow was $123 million, a change of -$38 million from H1 2025.
-   The change from the prior year was driven entirely by working capital, largely due to the timing of collections and disbursements, as well as higher incentive compensation payout.

#### Debt Repayment

-   Q2 2026 Debt Repayment was -$72 million.
-   H1 2026 Debt Repayment was -$211 million.
-   CCC Intelligent Solutions Holdings Inc. repurchased $75 million face value of 2028 bonds in the open market at a discount of approximately 3%.
-   Total H1 debt reduction was $218 million.

#### Other Operational Metrics

-   Q2 2026 ACV Organic Growth was 1.5%, an increase of 20 bps year-over-year.
-   H1 2026 Subscription Organic Growth was 1.2%, an increase of 60 bps year-over-year.
-   H1 2026 Recurring Organic Growth was 0.7%.

### FY 2026 Guidance and Outlook

CCC Intelligent Solutions Holdings Inc. reaffirmed its FY 2026 guidance, assuming the LS&H divestiture closes by year-end. ACV Organic Growth is expected to be in the lower half of the 2-3% range, and revenues including discontinued operations are projected to be approximately $2,350 million, with a decline due to strategic disposals. Free Cash Flow is anticipated to be at the low end of the $365 million to $435 million range, impacted by one-time costs for the LS&H transaction and cost savings initiatives.

### Related Stocks

- [CCC.US](https://longbridge.com/en/quote/CCC.US.md)

## Related News & Research

- [CitroTech Provides Q2 2026 Business Update in Letter to Shareholders](https://longbridge.com/en/news/295561956.md)
- [Algorhythm Holdings to Announce its Financial Results for the Second Quarter of 2026](https://longbridge.com/en/news/295634378.md)
- [Brisanet board okays Q2 2026 interim financial statements](https://longbridge.com/en/news/295590194.md)
- [Can Gold Make a New High in 2026?](https://longbridge.com/en/news/295569739.md)
- [GenScript Biotech announces Legend Biotech Form 6-K for Q2 ended June 30, 2026](https://longbridge.com/en/news/295534476.md)